Epidermal Growth Factor Gel – Generic

Epidermal Growth Factor Gel (Generic) is a topical formulation designed to support the healing of chronic wounds, particularly diabetic foot ulcers. Manufactured by Bharat Biotech International, the gel contains a synthetic form of epidermal growth factor (EGF), a naturally occurring protein that stimulates cell proliferation and tissue regeneration. The product is supplied in a 15‑gram tube, providing multiple applications for outpatient wound‑care regimens. Packaging options include single, triple, or sextuple gel units, allowing patients and clinicians to select the most appropriate supply based on treatment length. The gel is classified under Diabetes Care, reflecting its primary indication for managing lower‑extremity ulcers associated with diabetes mellitus.

Product Overview

This section provides a concise summary of the key attributes of Epidermal Growth Factor Gel. The formulation is intended for external use only and is packaged in a sealed, tamper‑evident tube to preserve sterility. Each tube delivers 15 grams of gel, which is sufficient for several weeks of treatment depending on ulcer size and frequency of application. The product is marketed as a generic alternative to branded EGF therapeutics, offering comparable biochemical activity at a cost‑effective price point. Storage requirements include room temperature conditions, protection from direct sunlight, and a recommended shelf life of 24 months when unopened.

What is Epidermal Growth Factor Gel

Epidermal Growth Factor (EGF) is a signaling peptide that binds to the epidermal growth factor receptor (EGFR) on skin cells, initiating pathways that promote cell division, migration, and new blood vessel formation. In the gel form, recombinant EGF is delivered directly to the wound surface, where it interacts with local cells to accelerate the natural repair cascade. The generic version from Bharat Biotech contains the same amino‑acid sequence as the reference biologic, ensuring identical biological activity while meeting regulatory standards for generic medications.

Uses and Benefits

The primary clinical indication for this gel is the adjunctive treatment of diabetic foot ulcers that have persisted despite standard wound‑care measures. When applied as directed, the gel can shorten the time to complete epithelialization, reduce the number of dressing changes required, and create a microenvironment less conducive to bacterial growth. Additional benefits include minimal systemic absorption, which limits the potential for off‑target effects, and a straightforward application process that does not require specialized equipment. Health‑care providers often integrate the gel into a comprehensive diabetic foot‑care plan that includes off‑loading, glycemic control, and regular foot inspections.

How It Works

The mechanism of action begins with the gel’s interaction with the wound surface, where recombinant EGF binds to EGFR receptors on resident skin cells. This binding activates intracellular signaling pathways such as PI3K‑Akt and MAPK, leading to increased DNA synthesis, cell migration, and proliferation of keratinocytes. Simultaneously, fibroblasts are stimulated to produce collagen and extracellular matrix proteins, while endothelial cells generate new blood vessels, enhancing oxygen and nutrient delivery to the ulcer site. The net effect is a faster transition from the inflammatory phase to the proliferative phase, resulting in more robust granulation tissue formation and quicker closure of the ulcer.

Dosage Guidelines

For optimal therapeutic effect, the manufacturer recommends applying a thin layer of the gel to the cleaned ulcer surface once daily, preferably after gentle irrigation with sterile saline. The amount should be sufficient to cover the entire wound bed without excessive pooling; a pea‑sized quantity is usually adequate for a typical 2‑centimeter ulcer. After application, the wound should be covered with a non‑adherent dressing to maintain a moist environment and protect the gel from mechanical disruption. Treatment duration varies depending on ulcer size and depth, but clinical studies have shown that consistent daily use for eight to twelve weeks often yields measurable improvements in wound area reduction.

Side Effects

Adverse events associated with topical EGF are generally mild and limited to the application site. The most commonly reported side effects include transient erythema, itching, or a burning sensation that typically resolves within a few hours. Rarely, patients may experience allergic dermatitis or localized edema, which warrants discontinuation of the product and consultation with a health‑care professional. Systemic absorption is minimal; however, patients with a known hypersensitivity to recombinant proteins should undergo a patch test before initiating therapy. Any signs of infection, increased pain, or delayed healing should prompt immediate medical evaluation.

Warnings and Precautions

Before using Epidermal Growth Factor Gel, clinicians should verify that the patient has a confirmed diagnosis of diabetes mellitus and that the ulcer is classified as a diabetic foot ulcer, as the gel is not indicated for other wound types. The product should be stored at room temperature, away from direct sunlight and moisture, and the tube must be kept tightly closed when not in use. Patients are advised to inform their health‑care team of any concurrent topical medications, especially antiseptics or antimicrobial dressings, to avoid potential interactions. Pregnant or lactating women should only use the gel if the expected benefit justifies the potential risk, and dosing should be supervised by a qualified physician.

Frequently Asked Questions

• Question: How often should I apply the gel?
  Answer: Apply once daily after cleaning the wound with sterile saline.
• Question: Can the gel be used with other topical antibiotics?
  Answer: It can be used alongside approved topical agents, but avoid applying other medicated creams within the same area at the same time; wait at least 15 minutes between applications.
• Question: Is the gel safe for all skin types?
  Answer: The formulation is non‑comedogenic and suitable for most skin types; however, individuals with a known allergy to recombinant proteins should perform a patch test or consult a clinician.
• Question: How long does it take to see improvement?
  Answer: Clinical observations indicate that wound area reduction may become noticeable after 2–3 weeks of consistent daily use, with full closure often occurring within 8–12 weeks.
• Question: Where can I find more scientific information?
  Answer: Detailed data are available from the National Center for Biotechnology Information (NCBI), the U.S. Food and Drug Administration (FDA), and the National Institutes of Health (NIH).

Related Products

• Regen-D Gel (Epidermal Growth Factor)